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Abstract
Introduction Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, inflammatory bowel diseases (IBD). Each class 
and type of medication available for the treatment of IBD has distinct characteristics and long-term effects that a patient may 
consider. We present the results of qualitative research that aimed to develop a descriptive framework that outlines the most 
relevant disease and/or treatment attributes for IBD treatment decisions and focuses on the patient perspective.
Methods This research employed a three-step approach: a literature review to identify a broad list of attributes, a focus 
group meeting including patients and clinicians to assess the relevance of the attributes, and two rounds of voting to name 
and define each attribute. The literature review was used to develop the initial list of attributes. Although the same attributes 
were defined for both UC and CD, the relative importance of each attribute to UC or CD was considered. The list of attrib-
utes was discussed and evaluated in the focus group meeting, which included eight patient representatives and nine gastro-
enterologists. Using feedback elicited from the focus group meeting, the research team developed a draft of the descriptive 
framework that grouped the attributes into domain subsets. All members of the focus group participated in two subsequent 
rounds of structured, online voting, which was used to refine the wording to name and define each attribute. Additionally, 
participants ranked all the attributes included in the descriptive framework to suggest which attributes were less relevant 
and could be omitted.
Results Among 574 publications retrieved from the databases and registries, we identified 32 eligible publications, and an 
initial list of attributes was developed. This list was refined during the focus group meeting, resulting in a draft descriptive 
framework of attributes within subsets of domains. The final descriptive framework was developed based on structured rounds 
of online voting to further refine attribute names and definitions. In the final descriptive framework, a total of ten attributes 
were identified: abdominal pain, other disease-related pain, bowel urgency, fatigue, risk of cancer and serious infections 
within the next 10 years, risk of mild to moderate complications, aesthetic complications related to treatment, emotional 
status, sexual life, and social life and relationships. These attributes were distributed across three domains: efficacy, compli-
cations and risk, and health-related quality of life.
Conclusions Through the identification of the ten most relevant attributes that influence patient decision making for IBD 
treatments, we developed a descriptive framework that should be considered by physicians when discussing IBD treatment 
options with their patients. The results of our qualitative research may also be helpful for the development of future IBD 
clinical studies and quantitative research.
This article is part of the topical collection “Formative qualitative 
evidence for health preference and outcomes research”.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4027 1-019-00407 -5) contains 
supplementary material, which is available to authorized users.
Extended author information available on the last page of the article
1 Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, 
systemic inflammatory bowel diseases (IBD) with signifi-
cant potential burden and resulting disability for patients 
[1, 2]. The incidence and prevalence of UC and CD vary 
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Key Points 
This research identified the ten most relevant attributes 
within three domains that can influence patients’ deci-
sions when making treatment choices for inflammatory 
bowel diseases (IBD).
The descriptive framework could be used to facilitate 
discussion between patients and physicians when review-
ing IBD treatment options.
Additional research to quantify the importance of each 
attribute in patient preferences is needed.
within different geographic locations. The most prevalent 
regions include North America, Northern Europe, and Aus-
tralia, but prevalence is increasing in regions where this has 
historically been low, such as Africa, South America, and 
Asia [3, 4].
Patients experience IBD differently based on the severity 
of the disease, the coexistence of other autoimmune diseases 
or extra-intestinal manifestations; and treatment for these 
conditions varies according to diverse patterns of clinical 
practice [5, 6]. Medications used for the treatment of IBD 
include aminosalicylates, glucocorticoids, immunomodula-
tors, biologics, and small molecules, with each class having 
distinct characteristics that will influence patient choice. 
Patient and physician preferences for IBD treatment options 
may also differ, thus communication between patients and 
physicians is crucial in the shared decision-making process 
[7].
Qualitative patient preference data identify which out-
comes, endpoints, or treatment attributes are relevant to 
patients, whereas quantitative patient preference data esti-
mate how much the different attributes matter to patients and 
the trade-offs that patients are willing to make [8]. Although 
the qualitative approach required to develop descriptive 
frameworks to describe treatment alternatives has been 
thoroughly described [9], there is limited information on 
which qualitative data or methods should be used to con-
duct a quantitative study on patient preferences. In the past, 
descriptive frameworks for health preference research were 
developed based on literature, non-preference-based health 
surveys, or expert opinion (top-down methods) [10]. More 
recently, the bottom-up methodology has been prevailing 
over the top-down methods. In this approach, patients are 
considered central to the process and their experiences and 
opinions on how the disease affects their lives are incorpo-
rated into the methodology [8].
Without a clear understanding of the patient perspective, 
the results of preference studies can be inconclusive or mis-
leading. Although there is no consensus on which qualitative 
methods should be applied after a literature review, there 
is agreement that literature searches alone are insufficient 
to adequately develop a descriptive framework for a robust 
preferences study [9]. The use of focus groups, in-depth 
interviews, and Delphi panels can be useful and provide a 
stronger methodology for qualitative research [11, 12].
To date, there is limited research that evaluates how dif-
ferent treatment characteristics may affect treatment choice 
for IBD patients, particularly with respect to the increasing 
range of mechanisms of action of new agents that will be 
entering the IBD space in the next few years. Moreover, the 
published literature on patients’ values/preferences for IBD 
treatment presents highly variable results [13–17].
The objective of the study presented here was to create a 
descriptive framework that includes the most relevant attrib-
utes that influence patients’ decision making regarding IBD 
treatment. The current research should serve as a solid foun-
dation for future preference elicitation studies analysing the 
utility values of the attributes.
2  Methods
A literature review, a focus group meeting, and structured 
online voting were conducted to identify the most relevant 
attributes associated with treatment decision making in IBD.
2.1  Literature Review
A literature review was performed on published health 
preference studies to identify preferences or attitudes 
towards pharmacological treatment in adult patients suf-
fering from mild to severe IBD conditions. To inform and 
facilitate the literature search, we used the Population/
Problem, Intervention, Comparison, Outcome, Study type 
(PICOS) framework. Both general and highly specialized 
international databases and registries (PubMed, Cochrane 
Library, International Society for Pharmacoeconomics and 
Outcomes Research, ClinicalTrials.gov, and the Health 
Preference Study and Technology Registry of the Interna-
tional Academy of Health Preference Research—https ://
hpstr .org/landi ng) were searched from January 1, 2000 to 
June 19, 2018, using the medical subject heading (MeSH) 
terms “preference”, “attitude to health”, “willingness to 
pay”, “time trade-off”, “standard gamble”, “conjoint”, 
“discrete choice”, “best–worst”, “utility”, “inflammatory 
bowel disease”, “Crohn disease”, and “ulcerative colitis” 
{e.g. ((((((inflammatory bowel disease[Title/Abstract] OR 
Crohn Disease[Title/Abstract] OR ulcerative colitis)[Title/
Abstract] AND ((preference[Title/Abstract] OR attitude 
to health[Title/Abstract] OR willingness to pay[Title/
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Abstract] OR time trade-off[Title/Abstract] OR discrete 
choice[Title/Abstract] OR conjoint[Title/Abstract] OR 
utility[Title/Abstract])) AND (“2000/01/01”[Date - Pub-
lication]: “2018/06/19”[Date - Publication])) AND (ther-
apy)) NOT osteopathy) NOT surgery}. Preference research 
of both qualitative and quantitative research as well as 
articles on input from patients and clinical experts were 
included. Publications related to surgery and alternative 
medical options were excluded.
Two reviewers independently screened the titles of the 
resulting citations for eligibility, and articles that were out 
of scope, duplicates, based on animal models, or studies in 
paediatric populations were discarded. Out of scope arti-
cles included publications focused on general satisfaction 
with health care provision, probiotics, preferences about 
being involved in shared decision making decisions, or 
satisfaction in the transition from paediatric to adulthood 
management of IBD. Publications that aimed to explore 
factors associated with health service utilization and pref-
erence for services, aimed to assess the appropriateness of 
immunosuppressive therapy in different scenarios, prefer-
ences on exercise, studies in pregnant women to evaluate 
their adherence, general reviews on adherence and prefer-
ences for psychological interventions, general overview/
reviews, opinion letters, overview of quality improvement 
initiatives in IBD, state or art of treatments and manage-
ment, preferences for diagnostic procedures were also con-
sidered out of scope.
Following the title screening step, the abstracts of the 
remaining articles were reviewed using the same criteria. 
The reviewers then independently screened the full text 
of the remaining articles following the abstract screening 
using the same criteria as the first two steps. Reviewers 
adjudicated conflicts through discussion or consultation 
with a third reviewer. After the title, abstract, and full-text 
screening steps, the reviewers identified and classified the 
relevant attributes across different domains (e.g. effective-
ness, side effects, health-related quality of life [HRQoL], 
and well-being). Generic attributes, such as reduction of 
side effects, were not considered in this research. Although 
the same attributes were defined for UC and CD, the 
relative importance of each attribute to UC or CD was 
considered.
2.2  Focus Group Meeting
We aimed to conduct a focus group of approximately 16–18 
participants to determine patients’ values and opinions 
regarding different treatment attributes. To have differ-
ent perspectives, an invitation letter to participate in the 
research was sent to patient associations and gastroenterolo-
gists from several countries. We aimed to recruit one patient 
representative per gastroenterologist. Those who expressed 
an interest in participating were contacted directly by the 
research team, and, at that point, the research project was 
explained in more detail. A written agreement was obtained 
if they were aged 18 years or older, were able to speak 
English, and could travel to the focus group meeting venue 
to participate.
The focus group meeting was conducted on September 
28, 2018 in Frankfurt, Germany. To determine the most 
relevant treatment attributes while considering both patient 
and physician perspectives, eight patient representatives and 
nine gastroenterologists were included. Patients represented 
local patient associations or local groups from countries 
such as Belgium, Canada, Spain, Germany, the UK, and 
Israel. The gastroenterologists were IBD specialists from 
academic medical centres with special interest and/or 
expertise in patient preferences, quality of life, and patient-
reported outcomes, and represented the same countries as 
the patients. In addition to providing their perspective on 
the attributes, the gastroenterologists also provided clinical 
expertise.
Information on the objectives, methodology, and results 
from the literature review was shared with all participants 
prior to the meeting and was further reviewed with the focus 
group participants during the focus group meeting. Addi-
tionally, the results of the literature review and an explana-
tion of the identified domains and attributes were provided. 
Through discussion, the focus group participants aligned on 
which attributes should be included in each domain. All par-
ticipants had the chance to state their opinions regarding the 
importance of each different treatment attribute.
Although the focus group meeting was not recorded, a 
transcript of the discussions was developed by a stenogra-
pher. Using the transcript, a tally was developed to indicate 
the number of participants who considered each attribute 
meaningful. These responses informed the subsequent draft 
of the descriptive framework that included the attributes 
grouped into domain subsets.
2.3  Structured Rounds of Voting
Following the focus group, the eight patient representatives 
and nine gastroenterologists participated in two rounds of 
online voting with the objective of refining the specific 
wording of the descriptive framework. The structured rounds 
of voting were designed to minimize the potential bias intro-
duced by the research team or dominant participants in the 
focus group meeting by providing patients with the oppor-
tunity to individually review the information and to con-
tribute feedback without the influence of other participants/
colleagues.
The simplified list of attributes included in the descriptive 
framework was shared during the first round of voting. For 
each attribute, a question provided suggested wording for 
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that attribute and asked whether the participant agreed or 
not; participants also had the opportunity to suggest addi-
tional changes to the wording. Additionally, participants 
were asked to rank all the attributes included in the descrip-
tive framework from most to least relevant (global ranking 
task). All responses from the wording questions and global 
ranking task were analysed using qualitative methods for 
free-text comments and frequencies for response options. 
The free-text comments were analysed to identify valuable 
context to better understand the responses or to improve 
the wording of the attributes. Based on the first round of 
voting, a refined version of the descriptive framework was 
developed.
The second round of voting aimed to determine which 
attributes could potentially be removed from the final 
descriptive framework. This method was used to minimize 
the final number of attributes to be similar to the maximum 
number of attributes that are currently tested in patient pref-
erence studies. The average number of attributes reported 
in the literature is six, with a minimum value of two and a 
maximum value of 12 [18]. While more consideration was 
given to the patients’ responses, the gastroenterologists’ 
responses were considered when there was not a clear con-
sensus among the patient responses. The total number of 
attributes included in the final list was based on the impor-
tance of each individual attribute provided by the patient 
participants as well as the experience of the research team 
in creating a valuable descriptive framework.
3  Results
3.1  Literature Review
The question statements used to inform the PICOS frame-
work are presented in Online Resource Table S1 (see the 
electronic supplementary material [ESM]). The literature 
search identified 574 records. The titles of these citations 
were screened for their relevance to the research topic, 
resulting in 109 articles to be further assessed for eligibil-
ity by abstract screening. The abstract screening step elimi-
nated 72 additional records. The full text of the remaining 
37 publications was evaluated based on pre-specified eli-
gibility criteria, and 32 publications on patient preferences 
were included in this research (Fig. 1). The most common 
reasons for excluding publications were out of scope (473), 
duplicates (20), and studies in the paediatric population (19).
A total of 127 attributes were identified based on the 
32 publications (Online Resource Table S2; see the ESM). 
These attributes were grouped into seven different domains 
(effectiveness, side-effects, HRQoL, well-being, available 
evidence, administration/convenience, and other).
3.2  Focus Group Meeting
Although not identified in the selected publications, skin 
cancer and herpes zoster are side effects in the treatment of 
IBD and a matter of concern for patients and physicians [19, 
20]. Based on the focus group discussion, these attributes 
were added to the list.
Table 1 shows the draft of the descriptive framework 
that was developed based on the feedback received during 
the focus group meeting. The draft included 16 relevant 
attributes within five different domains (efficacy, complica-
tions/risk, HRQoL/well-being, administration, and cost/co-
payment). Pain, stool control (specifically defined by bowel 
urgency), rectal bleeding, endoscopic results, fatigue/loss 
of energy, and rapidity of action of treatment were the most 
valued efficacy attributes based on the focus group meeting. 
Among the complication and risk attributes, the participants 
selected the risk of life-threatening cancer and serious infec-
tions within the next 10 years, risk of mild to moderate com-
plications, aesthetic complications related to treatment, and 
the need to remain on steroids as being the most relevant. 
HRQoL and well-being attributes, such as emotional status, 
sexual life, social life and relationships, and functional per-
formance in daily activities, as well as treatment administra-
tion (mode, frequency, and place of administration) and cost 
of treatment in general were also valued by the participants 
in the focus group meeting.
3.3  Structured Voting Rounds
A refined version of the descriptive framework was devel-
oped after the first round of voting. The full survey used in 
the first round of voting is available in the ESM. The number 
of attributes included in the structured voting was based on 
the global ranking task included in the first round of vot-
ing (Table 1). Stool control, pain, and fatigue/loss of energy 
were considered more important than endoscopic results, 
rectal bleeding, treatment administration, and cost accord-
ing to patient participants. The attributes that received lower 
ranking were removed from the attribute list. Following the 
first round of structured voting, the descriptive framework 
included 14 attributes within three different domains (effi-
cacy, complications/risk, and HRQoL/well-being).
During the second round of voting, participants expressed 
which attributes they would most likely remove from the final 
draft of the descriptive framework (Fig. 2). Stool frequency, 
rapidity of treatment action, and functional performance in 
daily activities were the most common attributes recom-
mended for removal and thus not included in the final list. 
Steroid dependency was removed from the final list because 
of the low ranking it received during the global ranking task of 
the first round of voting (12th place) as well as due to patient 
and physician feedback received during the second round of 
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voting. The full survey used in the second round of voting is 
available in the ESM. The final descriptive framework gener-
ated from the results of the structured surveys included ten 
attributes, grouped into three domains (efficacy, complica-
tions/risk, and HRQoL; Table 2).
4  Discussion
This study reports the process and results of a three-step 
approach to understand the attributes that patients most 
highly value when making decisions about IBD treat-
ment. To our knowledge, this research is the first study that 
defines a descriptive set of attributes based on input from 
patients with IBD. Our research could serve as a foun-
dation for future quantitative studies that aim at defining 
the importance of these attributes when making treatment 
decisions for IBD; the attributes presented here should 
be adapted to the specific needs of the study. In order to 
proceed to quantitative research, levels should be assigned 
to the selected attributes and should be tested in a patient 
preferences study. Results from this type of study could 
also be valuable in directing the evolution of endpoints 
used in future IBD interventional trials.
This research highlights the ten most relevant attributes 
across domains of efficacy, complications/risk, and HRQoL 
that are most influential to a patient’s decision regarding IBD 
treatment. The resulting practical descriptive framework will 
enable investigators to conduct further quantitative research 
to better understand the priorities of patients with IBD and 
to estimate the relative importance of each attribute/levels 
by means of discrete choice methods. When these levels of 
importance are clear, the quantification of how much more 
important one attribute may be compared to another can be 
communicated not only to other patients, but also to other 
stakeholders.
Of the attributes not deemed relevant by patients dur-
ing the second round of online voting, we speculate that 
Fig. 1  Literature flow diagram. 
*Used as a complementary 
source to confirm that all the 
relevant endpoints in clinical 
investigation had been identi-
fied. ISPOR International 
Society for Pharmacoeconomics 
and Outcomes Research, NIH 
National Institutes of Health
*Used as a complementary source to confirm that all the relevant endpoints in clinical investigation had 
been identified.









Out of scope: 421
109 citations passed the 
title review
37 citations passed the 
abstract/summary review and 
entered in the full text review
32 articles passed full-text 
screening and were included for 
data extraction and synthesis
72 articles excluded by abstract:
Pediatric studies: 1
Opinion letters: 2
Clinical opinion articles: 4
Editorial: 1
General reviews without specific data on preferences: 10
Focused on exercise or probiotics: 2
Out of scope: 52
32 additional abstracts/summaries:*
NIH and ClinicalTrials.gov: 32
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“functional performance in daily activities” was excluded 
from the final list because patients likely associate func-
tional performance with symptom resolution. Interestingly, 
stool frequency was not considered as relevant for patients 
as bowel urgency (defined as the need to rush to the toilet 
to avoid an accident), and therefore was dropped from the 
list. The need to remain on steroids was also deprioritized 
(considering the gastroenterologist perspective); never-
theless, aesthetic complications (most of them related to 
prolonged steroid exposure) was kept as a relevant attrib-
ute, indicating that steroid dependency is still a matter of 
concern.
In a recent study that used an online iterative Delphi con-
sensus process to develop an instrument to measure IBD-
related disability, authors agreed to include ten items of high 
importance to both patients and physicians (abdominal pain, 
body image, education and work, emotions, energy, interper-
sonal interactions, joint pain, regulating defecation, sexual 
functions, and sleep) within the tool and are in agreement 
with the attributes identified in the current study presented 
here [21]. The results of the current research are also con-
sistent with previous studies that demonstrated that patients 
rate quality of life higher than gains in productivity [16], and 
improvements in quality of life and symptom control are pri-
ority treatment objectives for IBD patients, with abdominal 
pain and bowel movement urgency being the most important 
symptoms [15].
The present research has several limitations. When used 
for qualitative literature review, the PICOS framework has 
several limitations that can impact the quality of clinical 
evidence obtained under its guidance [22]. Acknowledged 
limitations of the PICOS framework for qualitative evidence 
research include the fact that the framework does not accom-
modate terms relating to qualitative research. For example, 
the “Intervention” and “Comparison” components are not 
relevant for qualitative research, which traditionally does 
not utilize interventions and control groups. Additionally, 
combining the “Population” and “Intervention” components 
generally retrieves references to quantitative research. For 
this reason, it is possible that we were unable to capture 
Table 1  Shortened list of attributes grouped in redefined domains 
agreed on in the focus group meeting and patients’ ranking from the 
first round of voting
HRQoL health-related quality of life





Fatigue/loss of energy 3
Rapidity of action of treatment 10
Complications/risk Risk of life-threatening cancer and seri-
ous infections within the next 10 years
6
Risk of mild to moderate complications 9
Aesthetic complications related to treat-
ment
8
Need to remain on steroids 12
HRQoL/well-being Emotional status 5
Sexual life 11
Social life and relationships 7
Functional performance in daily activi-
ties
4
Administration Treatment administration 15
Cost/co-payment Cost 16
Fig. 2  Frequencies of stated 
attributes dropped by patients. 
*Used as a complementary 
source to confirm that all the 
relevant endpoints in clinical 
investigation had been identified
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and include all relevant publications. Another limitation of 
the literature review is that only previous health preference 
studies were included. By doing so, we may have missed 
concepts and themes from other types of studies that could 
have provided relevant attributes. The focus group meeting 
has inherent limitations that need to be acknowledged [23]. 
Focus groups may be influenced by one or several group 
members dominating the discussion and articulating their 
opinions alone, thus, limiting the opinions of other partici-
pants. It is also possible that the research team and its facili-
tation of the discussion may have influenced the participants’ 
responses, or that the patient voice may not exhibit the same 
weight as the physicians. Finally, the patient participants 
in this study may not convey the voice of all patients with 
IBD, but rather the experience limited to this small group. 
However, the structured rounds of voting were created to 
minimize the potential bias introduced by more dominant 
participants in the focus group meeting. The focus group 
and the online structured voting rounds may also be limited 
by the small number of participants. Thus, the generaliz-
ability of the interpretation and conclusions may be affected. 
Finally, the same attributes were defined for UC and CD, as 
all the attributes included were considered meaningful for 
patients with both diseases. We acknowledge that the relative 
importance of attributes differs across diseases and should 
be addressed in a quantitative study.
A key strength of this research was the use of multiple 
approaches to identify relevant and valuable attributes in 
the form of literature review, focus meetings comprised of 
both patient and physician participants, and structured online 
rounds of voting to provide a broad understanding of the 
attributes that may influence IBD treatment decision-mak-
ing. Although the opinions of both patients and physicians 
were taken into consideration in this research, more consid-
eration was given to patients’ responses during prioritization 
of the attributes, resulting in elimination of some attributes 
from the final list. Prioritization of the patient perspective 
in this study is consistent with recent statements from the 
National Health Council for the development of patient-cen-
tred measures, including those for the assessment of patient 
preferences for treatment alternatives [24]. An additional 
strength of this study is the broad regional representation 
and physicians’ clinical practice patterns.
5  Conclusions
This research identified the ten most relevant attributes that 
influence patients when making treatment choices. The 
descriptive framework developed from this study provides 
a better understanding of real-world decision making for 
patients with IBD and should be considered by physicians 
and nurses when discussing treatment options with patients. 
The current research serves as the foundation for future stud-
ies that will evaluate the utility of these attributes within 
clinical practice.
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